跳至主要内容
临床试验/ISRCTN24885065
ISRCTN24885065进行中(未招募)Unknown

Ketone supplementation to improve cardiac energetics and function

niversity of Leeds0 个研究点目标入组 90 人开始时间: 2023年5月4日最近更新:
适应症

试验速览

阶段
Unknown
状态
进行中(未招募)
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Eligibility criteria for diabetes patients in this study:
  • 1. Men and women >18 years of age
  • 2. 6.0 <= HBA1c <= 10% at screening (for T2D cohort)
  • 3. Ability and willingness to provide written informed consent and to comply with the requirements of the study
  • Eligibility criteria for patients with an established heart failure diagnosis:
  • 1. Men and women >18 years of age
  • 2. Ability and willingness to provide written informed consent and to comply with the requirements of the study
  • 3. Prior diagnosis of non-ischemic heart failure
  • 4. LV ejection fraction of <50% on prior CMR or echocardiography scans
  • 5. For participants with T2D: 6.0 <= HBA1c <= 10% at screening
  • Eligibility criteria for the healthy volunteers:
  • 1. Men and women >18 years of age
  • 2. Mean HBA1c< = 6%
  • 3. Ability and willingness to provide written informed consent and to comply with the requirements of the study

排除标准

  • Exclusion criteria for diabetes patients:
  • 1. History of coronary artery disease, previous CABG, angioplasty or myocardial infarction
  • 2. Known HF or reduced LVEF on baseline CMR (<50%)
  • 3. Female participants who are pregnant, lactating or planning pregnancy during the course of the study
  • 4. Renal impairment (eGFR <30 ml/min/m2)
  • 5. Participation in a clinical trial in the preceding 12 weeks
  • 6. Contra-indications to CMR or to dobutamine or gadolinium
  • 7. Any type of diabetes other than T2D
  • Exclusion criteria for patients with established heart failure diagnosis:
  • 1. Significant renal impairment (eGFR <30 ml/min/m2)
  • 2. Female participants who are pregnant, lactating or planning pregnancy during the course of the study
  • 3. Participation in a clinical trial of an investigational medicinal product in the preceding 12 weeks
  • 4. Contra-indications to MRI
  • 5. Known hypersensitivity to dobutamine or gadolinium
  • 6. History of coronary artery disease, previous CABG, angioplasty or myocardial infarction
  • 7. Any type of diabetes other than T2D
  • Exclusion criteria for healthy controls:
  • 1. Any type of diabetes
  • 2. Significant renal impairment (eGFR <30 ml/min/m2)
  • 3. Female participants who are pregnant, lactating or planning pregnancy during the course of the study
  • 4. Participation in a clinical trial of an investigational medicinal product in the preceding 12 weeks
  • 5. Contra-indications to MRI
  • 6. Known hypersensitivity to dobutamine or gadolinium
  • 7. History of coronary artery disease, previous CABG, angioplasty or myocardial infarction
  • 8. Known HF or reduced LVEF on baseline CMR (<50%)

研究者

发起方
niversity of Leeds

相似试验